Navigation Links
Arpida Presents Data on Iclaprim at Scientific Congress in Germany
Date:11/2/2007

d that it has received approval from the US FDA to initiate Phase II trials with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

An oral formulation of iclaprim has successfully completed three Phase I trials: an ADME study (absorption, distribution, metabolism and excretion) with radiolabelled compound, a Phase I bioavailability trial with a solution and one with a capsule formulation. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is about to enter Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertain
'/>"/>

SOURCE Arpida Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NimbleGen presents new tech for comparing microbe DNA
2. Wisconsin Technology Network presents symposium on saving lives by the use of Information Technology
3. Thieme Presents Unique Technology Angle at Gov.s Conference
4. UW-Madisons Beebe wins scientific award
5. Researchers say scientific reporting needs more perspective, less hype
6. Wisconsin stands at the center of scientific efforts to avert flu epidemics
7. Growth prompts new location for scientific instrument manufacturer
8. UW stem cell guru outlines scientific and political future
9. Wisconsin biotech sector featured in scientific magazine
10. Scientific Protein Laboratories Acquired by New York firm
11. GenTel Appoints Burke to its Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015  BioClinica®, Inc., a leading specialty ... announced that clinical trial professionals representing 20 ... annual European User Conference in ... use of its eClinical technologies to overcome ... the Microsoft Office-Smart OnPoint CTMS; Express EDC; ...
(Date:3/4/2015)... 2015 Lancée par ... en décembre 2011, l,étude collaborative française ... qui compare   l es microsphères en ... dans le carcinome hépatocellulaire avancé, a recruté plus ... avancé   ; les résultats sont attendus fin ...
(Date:3/3/2015)... 3, 2015 NASA astronaut Scott Kelly , ... to spend a year living and working on the International ... 5:30 to 7 a.m. EDT Monday, March 9. ... he completes the final weeks of his training. The interviews ... NASA Television highlighting his mission training and previous spaceflights. ...
(Date:3/3/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and Chief Executive Officer of Neurocrine Biosciences, will be ... The live presentation takes place on ... presentation will be webcast and may be accessed on ... Listeners are encouraged to visit the website approximately ...
Breaking Biology Technology:BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2
... CAPE CORAL, Fla., Nov. 2, 2011 Nature,s Bioceuticals, a ... News ) announced that it has reached an agreement in ... life changing results for hundreds of millions of people worldwide ... agreement will be executed in the coming week, at which ...
... rise, but solar cells are only as efficient as ... of a new professor at Northwestern University,s McCormick School ... new material that absorbs a wide range of wavelengths ... solar technology. A paper describing the findings, "Broadband ...
... Nov. 2, 2011 Advanced BioMedical Technologies Inc. (OTCQB:ABMT), ... is pleased to announce the formation of its scientific ... distinguished physicians and scientists. The combined expertise of the ... strategic input as the Company continues to develop its ...
Cached Biology Technology:Nature's Bioceuticals Close to Finalizing Strategic Transaction in One of the Largest Drug Markets 2Nature's Bioceuticals Close to Finalizing Strategic Transaction in One of the Largest Drug Markets 3Solar power could get boost from new light absorption design 2Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 2Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 3Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 4Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 5Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 6Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 7
(Date:2/5/2015)... Jan. 28, 2015 Research and Markets ... of the "Global Biometrics Market (2014-2020): Market ... Countries " report to their offering. , ... Asia-Pacific is anticipated to overtake ... to increasing government spending towards IT security, government ...
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform ... State of Washington,s Department of Licensing, in the ... issuance system for driver,s licenses and identification cards to its ... development will start in January 2015, with enrollment and card ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a ... discovery, announced the launch of a TR-FRET (time ... company,s Transcreener UDP Assay, a high throughput screening ... new assay will allow for sensitive detection of ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... Medical Institute researchers and their colleagues have discovered a ... a cancer-causing virus found in mice. Their findings describe ... retrovirus that is native to rodents. , The researchers ... of prostate cancer. The patients in the study have ...
... announce today that gibbons, arboreal primates that inhabit the jungles ... that is present in the genomes of all other primates, ... event that occurred approximately 25 million years ago. Their ... journal Genome Research . , Agouti signaling protein ( ...
... novel genes within the tumors of women with early stage ... are not at risk for early relapse or cancer-related death. ... 1 issue of Clinical Cancer Research. , "The HOXB13 and ... of relapse in hormone-receptor positive breast cancer treated with tamoxifen," ...
Cached Biology News:New human retrovirus originated in mice 2New human retrovirus originated in mice 3New human retrovirus originated in mice 4Major obesity gene is 'lost in the shuffle' 2Mayo Clinic study finds two genes predict outcome for breast cancer patients 2
Mouse polyclonal antibody to BTG2 - BTG family, member 2...
These 96-well 0.2 ml thin-wall PCR plate caps are caps that are used to seal 96-well, 0.2 ml thin-wall PCR plates. Supplied as 300 caps....
... Source of colony stimulating factors for assays ... spleen, blood and fetal liver. Suitable ... CFU-G and CFU-GEMM when added to methylcellulose ... addition of erythropoietin. Will also support ...
... bromide), 50mg/vial. MTT is a pale yellow ... to yield a dark blue formazan product. ... freshly dead cells do not cleave significant ... component of Chemicons MTT assay kit, Catalog ...
Biology Products: